Bilateral prophylactic mastectomy reduces @entity0 risk in XXXX and @entity2674 mutation carriers: the PROSE Study Group.

@entity1 @entity0 @entity5345 @entity2674 @entity14049
PURPOSE: Data on the efficacy of bilateral prophylactic mastectomy for @entity0 risk reduction in @entity1 with @entity5345 and @entity2674 ( @entity14049 ) mutations are limited, despite the clinical use of this risk-management strategy. Thus, we estimated the degree of @entity0 risk reduction after surgery in @entity1 who carry these mutations. @entity1 AND METHODS: Four hundred eighty-three @entity1 with disease-associated germline @entity14049 mutations were studied for the occurrence of @entity0 . Cases were mutation carriers who underwent bilateral prophylactic mastectomy and who were followed prospectively from the time of their center ascertainment and their surgery, with analyses performed for both follow-up periods. Controls were @entity14049 mutation carriers with no history of bilateral prophylactic mastectomy matched to cases on gene, center, and year of birth. Both cases and controls were excluded for previous or concurrent diagnosis of @entity0 . Analyses were adjusted for duration of endogenous ovarian hormone exposure, including age at bilateral prophylactic oophorectomy if applicable. RESULTS: @entity0 was diagnosed in two (1.9%) of 105 @entity1 who had bilateral prophylactic mastectomy and in 184 (48.7%) of 378 matched controls who did not have the procedure, with a mean follow-up of 6.4 years. Bilateral prophylactic mastectomy reduced the risk of @entity0 by approximately 95% in @entity1 with prior or concurrent bilateral prophylactic oophorectomy and by approximately 90% in @entity1 with intact ovaries. CONCLUSION: Bilateral prophylactic mastectomy reduces the risk of @entity0 in @entity1 with @entity14049 mutations by approximately 90%.
